NDA 208261 · Msd Sub Merck
Zepatier
Elbasvir, Grazoprevir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor
NovelBreakthrough therapyPriority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: Dec 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jan 28, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
22 Phase 3, 0 recruiting
FAERS reports
4,249
1,435 serious, 123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with ZEPATIER. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...
What it is approved for
From the label in effect Mar 13, 2026.
ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration (2.2) ] . ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated for treatment of chronic HCV genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations. ( 1 )
Mechanism: ZEPATIER is a fixed-dose combination of elbasvir and grazoprevir which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 9, 2021 Supplement 7 · Efficacy LabelLetter
- Jan 28, 2016 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyReviewSummary ReviewLetter
1 products under this application
- ZEPATIER · ELBASVIR 50MG; GRAZOPREVIR 100MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Elbasvir" as an intervention, any sponsor and status, largest first.
- Study of Oral Treatments for Hepatitis CPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT02786537 · 1,275 participants · Start Jun 2016 · Primary completion Jun 13, 2019
Drug: SOF/LDV (sofosbuvir/ledipasvir); PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) and 2 more · For: Chronic Hepatitis C
Sites: Little Rock, Arkansas; Palo Alto, California; San Diego, California · 38 sites in all
- A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01717326 · 573 participants · Start Feb 7, 2013 · Primary completion Feb 23, 2015
Drug: Grazoprevir; Elbasvir and 2 more · For: Hepatitis C
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02251990 · 489 participants · Start Jan 28, 2015 · Primary completion Sep 27, 2016
Drug: Grazoprevir/Elbasvir; Placebo · For: Hepatitis C
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02332707 · 443 participants · Start Jan 22, 2015 · Primary completion Sep 16, 2016
Drug: Grazoprevir; Uprifosbuvir and 4 more · For: Hepatitis C
- Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02105467 · 421 participants · Start Jun 5, 2014 · Primary completion Feb 26, 2015
Drug: Grazoprevir 100mg / Elbasvir 50 mg FDC; Placebo to Grazoprevir / Elbasvir 50 mg FDC · For: Chronic Hepatitis C Virus
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02105701 · 420 participants · Start Jun 5, 2014 · Primary completion Mar 24, 2015
Drug: Grazoprevir + Elbasvir; Ribavirin · For: Hepatitis C Infection
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02332720 · 413 participants · Start Jan 28, 2015 · Primary completion Sep 19, 2016
Drug: Grazoprevir; Uprifosbuvir and 4 more · For: Hepatitis C
- Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02203149 · 399 participants · Start Aug 1, 2014 · Primary completion Oct 2, 2015
Drug: Grazoprevir; Elbasvir and 2 more · For: Hepatitis C
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue958
- headache756
- nausea558
- insomnia313
- diarrhoea256
- drug dose omission253
- vomiting182
- adverse event150
- pneumonia147
- hepatitis c137
- arthralgia133
- pruritus123
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 656 |
| 2017 | 2,382 |
| 2018 | 684 |
| 2019 | 242 |
| 2020 | 79 |
| 2021 | 39 |
| 2022 | 30 |
| 2023 | 14 |
| 2024 | 69 |
| 2025 | 45 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zepatier (Elbasvir/Grazoprevir)
2024 spending
$224K
Beneficiaries
14
32 claims
Per beneficiary
$15,975
$249.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,126,256 |
| 2021 | $616,424 |
| 2022 | $343,063 |
| 2023 | $467,651 |
| 2024 | $223,652 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.
Ahmed H, Abushouk AI, Menshawy A, et al. · Ann Hepatol 2018 · Meta-Analysis, Review
- Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
Zhou S, Williford SE, McGivern DR, et al. · Antiviral Res 2018 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
Feng HP, Caro L, Fandozzi CM, et al. · J Clin Pharmacol 2018 · Comparative Study, Controlled Clinical Trial
- Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
Khlaiphuengsin A, Chuaypen N, Sodsai P, et al. · PLoS One 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Liu J, Guo M, Ke L, et al. · Front Public Health 2022 · Systematic Review
- Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
Nangia G, Vierling JM, Kwo P, et al. · J Viral Hepat 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.